Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
115
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,902.25 | 23.79 | 0.30% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,676.74 | 218.44 | 0.49% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,600.92 | 10.42 | -0.05% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,275.25 | 11.99 | 0.19% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |